Press Releases

Press Releases
Date Title and Summary View
Feb 14, 2018 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) today announced the Company's Board of Directors authorized the repurchase of an additional $5 billion of the Company's common stock. This open-ended program is effective immediately. Purchases may be made in the open market or in privately ...
Feb 9, 2018 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced the successful pricing of four series of senior unsecured notes for an aggregate principal amount of $4.5 billion. Of these notes, $500 million will mature in 2021 and will bear interest at an annual rate of 2.875 percent, $1.0 bill...
Feb 8, 2018 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced its intention to offer, subject to market and other conditions, senior unsecured notes under a shelf registration statement on Form S-3 on file with the Securities and Exchange Commission. The interest rate, the maturity da...
Feb 6, 2018 Study met its primary endpoint demonstrating significant improvement in progression-free survival (PFS) with POMALYST®/IMNOVID® in combination with bortezomib and dexamethasone (PVd) compared with bortezomib and low-dose dexamethasone SUMMIT, N.J.--(BUSINESS WIRE)-- Celgen...
Feb 2, 2018 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced that its wholly-owned subsidiary, Blue Magpie Corporation, has commenced its previously announced tender offer for all outstanding shares of common stock of Juno Therapeutics, Inc. (NASDAQ: JUNO) at a price of $87.00 per share, ...
Feb 1, 2018 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) plans to present at two upcoming investor conferences where Celgene management will provide an overview of the Company. The conferences will be webcast live and will be available in the Investor Relations section of the Company's website at www.ce...
Jan 29, 2018 Executive Chairman Bob Hugin to retire and step down from Celgene's Board of Directors effective February 5, 2018 During Bob Hugin's 19-year tenure, Celgene expanded from 200 to 7,500 employees, received approvals for 8 therapies across 10 diseases in more than 70 countries and delivered industry-...
Jan 25, 2018 - Finished 2017 with strong operating and financial momentum - Celgene recently announced two strategic transactions enhancing long-term growth prospects SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) reported operating results for the fourth quart...
Jan 22, 2018 Acquisition Will Add Novel Scientific Platform and Manufacturing Expertise to Celgene's Research and Operational Capabilities JCAR017 is Expected to be a Significant Growth Driver Beyond 2020 with Potential Global Peak Sales of Approximately $3B Reaffirming 2020 Fin...
Jan 19, 2018 Phase II LAPACT trial results reported on the safety and efficacy of ABRAXANE + gemcitabine induction therapy on tumor burden, disease control, and symptoms SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) today announced primary endpoint findings and updated resul...
FirstPrevious
4
... NextLast
Add to Briefcase = add release to Briefcase